Define the disease signal
Identify measurable biological signals that distinguish the target disease state and can anchor a responsive therapeutic design.
Disease-responsive therapeutics
Engineering disease-responsive therapy.
CircuraBio is building therapeutic programs designed around disease-relevant biological signals and controlled response—applying a common engineering framework across multiple disease systems.
Platform
A common engineering framework across distinct disease systems.
Our programs begin with disease-relevant biology, pair it with a controlled therapeutic response, and advance through stage-gated experimental validation.
Program the response
Engineer therapeutic activity to respond to the selected biology with the control, specificity and output required by the indication.
Advance with evidence
Move candidates from in vitro work through small- and large-animal studies toward human translation using explicit development gates.
Portfolio
A growing pipeline of disease-responsive programs.
Programs span endocrine and metabolic disease, musculoskeletal disorders, immunology, oncology and systemic disease. The development rail shows the current stage of each candidate.
Stage position is categorical rather than a percentage-complete estimate. CB-001 in Type 1 diabetes is shown as advancing from small-animal toward large-animal preclinical work.
Endocrine / Metabolic
Type 1 diabetes
CB-001
Advancing: preclinical small animal → large animal
Type 1 diabetes / obesity
CB-002
Preclinical · small animal
Type 1 diabetes / obesity
CB-003
Preclinical · small animal
Type 2 diabetes
CB-001
Preclinical · small animal
Musculoskeletal disorders
Fibrodysplasia ossificans progressiva
CB-005
Preclinical · small animal
Osteogenesis imperfecta
CB-006
Preclinical · small animal
Trauma / heterotopic ossification
CB-006 / CB-007
Preclinical · small animal
Muscular dystrophy
CB-008
Preclinical · small animal
Immunologic
Transplant rejection
CB-006
Preclinical · small animal
Transplant rejection
CB-009
Preclinical · small animal
Oncology
Oncology
CB-006 / CB-010
Preclinical · small animal
Systemic disease
Inflammaging
CB-006
Preclinical · small animal
Current stage: all listed programs remain preclinical.
Program stages are shown by current development phase.